Raras
Buscar doenças, sintomas, genes...
Distrofia corneana, tipo macular
ORPHA:98969CID-10 · H18.5CID-11 · 9A70.YOMIM 217800DOENÇA RARA

A Distrofia Macular da Córnea (DCM) é uma condição rara e grave que afeta a córnea, a "janela" transparente na frente do olho, especificamente a sua camada central e mais espessa (o estroma). Ela se caracteriza pelo surgimento de manchas opacas e com contornos pouco definidos em ambos os olhos, que se localizam no estroma, tornando-o turvo. Com o tempo, essa condição leva a uma perda grave da visão.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Distrofia Macular da Córnea (DCM) é uma condição rara e grave que afeta a córnea, a "janela" transparente na frente do olho, especificamente a sua camada central e mais espessa (o estroma). Ela se caracteriza pelo surgimento de manchas opacas e com contornos pouco definidos em ambos os olhos, que se localizam no estroma, tornando-o turvo. Com o tempo, essa condição leva a uma perda grave da visão.

Publicações científicas
230 artigos
Último publicado: 2026 Apr 10

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.0
United States
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: H18.5
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Características mais comuns

90%prev.
Anormalidade do metabolismo/homeostase
Muito frequente (99-80%)
90%prev.
Opacificação puntiforme da córnea
Muito frequente (99-80%)
90%prev.
Cristais corneanos
Muito frequente (99-80%)
90%prev.
Opacificação do estroma corneano
Muito frequente (99-80%)
55%prev.
Erosões corneanas recorrentes
Frequente (79-30%)
55%prev.
Acuidade visual severamente reduzida
Frequente (79-30%)
15sintomas
Muito frequente (4)
Frequente (3)
Ocasional (4)
Sem dados (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 15 características clínicas mais associadas, ordenadas por frequência.

Anormalidade do metabolismo/homeostaseAbnormality of metabolism/homeostasis
Muito frequente (99-80%)90%
Opacificação puntiforme da córneaPunctate opacification of the cornea
Muito frequente (99-80%)90%
Cristais corneanosCorneal crystals
Muito frequente (99-80%)90%
Opacificação do estroma corneanoOpacification of the corneal stroma
Muito frequente (99-80%)90%
Erosões corneanas recorrentesRecurrent corneal erosions
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico230PubMed
Últimos 10 anos79publicações
Pico202510 papers
Linha do tempo
2026Hoje · 2026🧪 2003Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

CHST6Carbohydrate sulfotransferase 6Disease-causing germline mutation(s) (loss of function) inDesconhecido
FUNÇÃO

Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues of keratan (PubMed:11278593, PubMed:11352640, PubMed:12218059, PubMed:17690104). Cooperates with B4GALT4 galactosyltransferase and B3GNT7 N-acetylglucosaminyltransferase to construct and elongate the sulfated disaccharide unit [->3Galbeta1->4(6-sulfoGlcNAcbeta)1->] within keratan sulfate polymer. Involved i

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Keratan sulfate biosynthesis
MECANISMO DE DOENÇA

Macular dystrophy, corneal

An ocular disease characterized by bilateral, progressive corneal opacification, and reduced corneal sensitivity. Onset occurs in the first decade, usually between ages 5 and 9. Painful attacks with photophobia, foreign body sensations, and recurrent erosions occur in most patients. The disease is due to deposition of an unsulfated keratan sulfate both within the intracellular space (within the keratocytes and endothelial cells) and in the extracellular corneal stroma. Macular corneal dystrophy is divided into the clinically indistinguishable types I, IA, and II based on analysis of the normally sulfated, or antigenic, keratan sulfate levels in serum and immunohistochemical evaluation of the cornea. Patients with types I and IA macular corneal dystrophy have undetectable serum levels of antigenic keratan sulfate, whereas those with type II macular corneal dystrophy have normal or low levels, depending on the population examined.

OUTRAS DOENÇAS (1)
macular corneal dystrophy
HGNC:6938UniProt:Q9GZX3

Variantes genéticas (ClinVar)

106 variantes patogênicas registradas no ClinVar.

🧬 CHST6: NM_021615.5(CHST6):c.15_16insATGCTGTGCG (p.Val6fs) ()
🧬 CHST6: NM_021615.5(CHST6):c.51del (p.Gln18fs) ()
🧬 CHST6: NM_021615.5(CHST6):c.231G>A (p.Trp77Ter) ()
🧬 CHST6: NM_021615.5(CHST6):c.614G>A (p.Arg205Gln) ()
🧬 CHST6: NM_021615.5(CHST6):c.631C>G (p.Arg211Gly) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 296 variantes classificadas pelo ClinVar.

74
15
207
Patogênica (25.0%)
VUS (5.1%)
Benigna (69.9%)
VARIANTES MAIS SIGNIFICATIVAS
CHST6: NM_021615.5(CHST6):c.15_16insATGCTGTGCG (p.Val6fs) [Pathogenic]
CHST6: NM_021615.5(CHST6):c.51del (p.Gln18fs) [Pathogenic]
CHST6: NM_021615.5(CHST6):c.231G>A (p.Trp77Ter) [Pathogenic]
CHST6: NM_021615.5(CHST6):c.614G>A (p.Arg205Gln) [Pathogenic]
CHST6: NM_021615.5(CHST6):c.631C>G (p.Arg211Gly) [Likely pathogenic]

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia corneana, tipo macular

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

1 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
81 papers (10 anos)
#1

Targeted AAV6 gene therapy restores corneal endothelial function in three hereditary corneal dystrophies.

Cell reports. Medicine2026 Mar 17

The corneal endothelium maintains corneal transparency and vision. Hereditary corneal dystrophies, including macular corneal dystrophy (MCD), Fuchs endothelial corneal dystrophy (FECD), and congenital hereditary endothelial dystrophy (CHED), cause progressive endothelial dysfunction, for which corneal transplantation is currently the main treatment. We evaluate an adeno-associated virus (AAV)-based gene therapy approach in preclinical models of MCD, FECD, and CHED. A refined intracameral injection method enables uniform endothelial transduction without corneal puncture. A single AAV6 administration supports sustained transgene expression in the corneal endothelium for over 18 months without detectable adverse immune responses. In MCD mice, AAV6-Chst5 reduces corneal opacification and restores keratan sulfate levels. In FECD mice, AAV6-Col8a2 prevents corneal opacity in 87.5% of treated eyes. In the CHED model, AAV6-Slc4a11 resolves corneal edema within 7 days. Single-cell RNA sequencing identifies Wnt5a as a downstream factor associated with MCD pathogenesis. These findings support the therapeutic potential of endothelial-targeted gene delivery for corneal endothelial disorders.

#2

Molecular characterization of CHST6 in Egyptian families with macular corneal dystrophy reveals recurrent and novel variants.

Ophthalmic genetics2026 Jan 21

The study aimed to identify pathogenic variants in the CHST6 gene in a cohort of Egyptian patients diagnosed with macular corneal dystrophy (MCD). Sanger sequencing of the CHST6 gene was performed in 16 individuals affected by MCD from nine unrelated Egyptian families, as well as in their available first-degree relatives. Surgical management data for affected individuals were also collected. Nine different pathogenic or likely pathogenic variants were identified, three of which were novel. All affected individuals carried homozygous mutations, consistent with autosomal recessive inheritance. Parental consanguinity was documented in eight of the nine families. All patients required surgery to restore vision. The mean age at corneal grafting in the first eye was 32.7 ± 8.9 years (range 17-44 years). This study broadens the genetic landscape of MCD by identifying novel CHST6 variants in an Egyptian cohort. The high rate of homozygosity highlights the significant role of consanguinity in shaping the genetic burden of rare diseases in Egypt and the wider Middle East and North Africa region.

#3

Keratan sulfate revisited: UPLC-MS/MS-based quantitative profiling reveals structural heterogeneity and deficiency in ocular pathologies.

Carbohydrate polymers2026 Mar 01

Keratan sulfate (KS) is a structurally unique glycosaminoglycan involved in various physiological processes. Dysregulated KS levels and sulfation modifications are associated with the development of various disorders. However, the absence of commercial KS standards and specific hydrolases has hindered accurate quantification and functional studies. To overcome these limitations, we prepared two structurally distinct KS disaccharide standards (Gal-GlcNAc6S and Gal6S-GlcNAc6S) from corneal and cartilaginous tissues, and obtained recombinant KS hydrolase through heterologous expression. Given that the total abundance of various sulfated KS disaccharides reflects overall KS content, a robust UPLC-MS/MS method was further developed for simultaneous quantification of multiple sulfated KS disaccharides. The developed methodology demonstrated exceptional sensitivity, achieving KS quantification from minimal biological inputs (500-1,000 cells or 1 mg tissue). Quantitative analysis revealed significant variation in KS distribution among distinct human ocular cell populations, with stromal cells exhibiting the highest abundance, followed by endothelial and epithelial cells. Notably, total KS expression in corneal specimens from macular corneal dystrophy (MCD) patients was reduced by over 90 % relative to keratoconus (KC). This study establishes a comprehensive platform for KS quantification and offers novel insights into its structure-function relationships within ocular tissues.

#4

Objective assessment of graft clarity and recurrence after penetrating keratoplasty for granular, lattice and macular corneal dystrophy using scheimpflug densitometry.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026 Apr

To evaluate long-term outcomes and recurrence patterns following penetrating keratoplasty (PKP) in granular (GCD), lattice (LCD), and macular corneal dystrophy (MCD), using Scheimpflug-based corneal densitometry (grayscale units-GSU) as an objective tool to assess graft clarity. In this retrospective single-center study, 99 eyes of 59 patients with GCD (n = 38), LCD (n = 30), or MCD (n = 31) were analyzed. A total of 112 PKPs, including 74 excimer laser-assisted PKPs, were evaluated. Clinical examinations included visual acuity, slit-lamp evaluation, and corneal tomography using the Pentacam HR. Clinical recurrence was defined as the appearance of dystrophy-specific changes within the graft. Corneal densitometry was assessed in the anterior, central, and posterior layers and the total corneal thickness at 0-2 mm and 2-6 mm zones. Follow-up ranged from 6 weeks to more than 5 years (5y+) postoperatively. A significant postoperative improvement in BCVA was observed in eyes with GCD and MCD, with sustained visual gains up to 4y and 5y postoperatively, respectively. GCD demonstrated the earliest and highest clinical recurrence rate, with all grafts affected by 5y. LCD showed delayed recurrence from 4y onward, while MCD did not show any recurrence within 5y. Corneal densitometry revealed a progressive increase in GSU in GCD and LCD, particularly in the anterior (GCD:5y / LCD:5y+) and central layers (GCD:4y / LCD:5y+). MCD showed stable GSU values throughout follow-up. Linear regression analysis showed the strongest GSU increase in LCD (slope = 1.65, R²=0.47) and GCD (slope = 0.94, R²=0.14), particularly in the anterior 0-2 mm zone. MCD showed minimal change across all layers and diameters. Scheimpflug-based corneal densitometry enables objective, layer-specific monitoring of graft clarity and recurrence after PKP. Recurrence rates differ significantly among dystrophy subtypes, highlighting the clinical utility of densitometry in tailoring follow-up strategies, particularly in GCD and LCD with high risk of recurrence.

#5

Understanding the role of hydration and hydration gradient in corneal disease.

Experimental eye research2026 Jan

Maintaining proper corneal hydration is critical for vision. Yet, a quantitative understanding of hydration throughout the corneal stroma is lacking. The purpose of this work is to to better understand the corneal hydration gradient including its origins, diagnostic utility, and role in different diseases. A theoretical model was developed for fluid flow in the cornea, which is driven largely by the stromal swelling pressure. The model employs a novel, first principles equation of state for stromal swelling pressure that captures the strong dependence on hydration that is observed experimentally. The model is then used to evaluate steady-state corneal hydration profiles. The results are used to analyze clinical observations in dry eye disease, Fuchs' dystrophy, and macular corneal dystrophy. The model is also applied to keratoconus where the authors hypothesize previously undetected hydration-related changes may occur secondary to structural and biomechanical changes. The model results show typical changes in water volume fraction across the cornea range from 1 to 5%, and are driven primarily by the osmolarity difference between the aqueous humour and tear film. The model also accurately captures changes in corneal thickness and hydration in several diseases, and illustrates the diagnostic utility of the corneal hydration gradient. The model accurately relates microscopic physical processes in the stroma to observable macroscopic changes in corneal thickness and hydration that is consistent with clinical observation. Use of corneal hydration gradient as a diagnostic could help distinguish factors influencing corneal hydration.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC159 artigos no totalmostrando 76

2026

Targeted AAV6 gene therapy restores corneal endothelial function in three hereditary corneal dystrophies.

Cell reports. Medicine
2026

Scanning electron microscopy of the descemet membrane in macular corneal dystrophy.

European journal of ophthalmology
2026

Molecular characterization of CHST6 in Egyptian families with macular corneal dystrophy reveals recurrent and novel variants.

Ophthalmic genetics
2025

Anterior Segment Optical Coherence Tomography in the Diagnosis of Corneal Stromal Dystrophies in Romania.

Maedica
2026

Keratan sulfate revisited: UPLC-MS/MS-based quantitative profiling reveals structural heterogeneity and deficiency in ocular pathologies.

Carbohydrate polymers
2026

Objective assessment of graft clarity and recurrence after penetrating keratoplasty for granular, lattice and macular corneal dystrophy using scheimpflug densitometry.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Deep Learning Model for Extensive Diagnosis of Corneal Deposits.

Cornea
2026

Understanding the role of hydration and hydration gradient in corneal disease.

Experimental eye research
2025

Simultaneous Type 1 and Type 2 Big-Bubble Deep Anterior Lamellar Keratoplasty (DALK) for Macular Corneal Dystrophy.

American journal of ophthalmology
2024

Visual and Refractive Outcomes of Different Bubble Types in Deep Anterior Lamellar Keratoplasty for Macular Corneal Dystrophy.

Journal of current ophthalmology
2025

Concordance Between Clinical and Pathological Diagnosis of Stromal Corneal Dystrophies in a Large Case Series.

Cornea
2026

Corrigendum to "Penetrating keratoplasty versus deep anteriror lamellar keratoplasty for macular corneal dystrophy: A meta-analysis" [Survey Ophthalomol., vol. 70 (2025) P480-488/ PMID: 39709033].

Survey of ophthalmology
2025

Efficacy and Safety of Penetrating Keratoplasty and Deep Anterior Lamellar Keratoplasty in Corneal Macular Dystrophy: A Systematic Review and Meta-Analysis.

Journal of ophthalmology
2025

Peripheral Macular Endothelial Dystrophy: Clinical, Histopathologic, Genetic and Functional Characterization.

American journal of ophthalmology
2024

Genetic implications of CHST6 gene mutations and their corneal microstructural changes in macular corneal dystrophy patients.

Molecular vision
2025

In Vivo Confocal Microscopy Findings in Corneal Stromal Dystrophies.

Diagnostics (Basel, Switzerland)
2025

Penetrating keratoplasty versus deep anteriror lamellar keratoplasty for macular corneal dystrophy: A meta-analysis.

Survey of ophthalmology
2025

Loss of carbohydrate sulfotransferase 6 function leads to macular corneal dystrophy phenotypes and skeletal defects in zebrafish.

The FEBS journal
2024

Trehalose extricates impaired mitochondrial and autophagy dysregulation in patient iPSC-derived macular corneal dystrophy disease model.

Stem cell research &amp; therapy
2025

Long-term prognosis of penetrating keratoplasty in a patient with limited form of Scleroderma- a case report.

European journal of ophthalmology
2024

Comparison of Scheimpflug Imaging (Pentacam HR) and Swept-Source Optical Coherence Tomography (CASIA2) in Eyes With Macular Corneal Dystrophy.

Cornea
2024

Macular corneal dystrophy with iridofundal coloboma in the same patient: a unique combination.

BMJ case reports
2024

Macular Corneal Dystrophy - Molecular Genetics as the Key in Treatment-Refractory Keratopathy.

Klinische Monatsblatter fur Augenheilkunde
2024

Deep anterior lamellar keratoplasty and penetrating keratoplasty in macular corneal dystrophy: comparison of visual and topographic outcomes and complications.

Arquivos brasileiros de oftalmologia
2023

Visual outcomes and recurrence rate of macular corneal dystrophy following phototherapeutic keratectomy in Saudi Arabia.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2024

The role of corneal endothelium in macular corneal dystrophy development and recurrence.

Science China. Life sciences
2023

Oxidative Stress and Cellular Protein Accumulation Are Present in Keratoconus, Macular Corneal Dystrophy, and Fuchs Endothelial Corneal Dystrophy.

Journal of clinical medicine
2023

Complications in deep anterior lamellar keratoplasty - A retrospective cross sectional interventional analysis in a large series.

Oman journal of ophthalmology
2022

Complications in deep anterior lamellar keratoplasty - A retrospective interventional analysis in a large series.

Indian journal of ophthalmology
2022

Macular Corneal Dystrophy in an Adolescent Managed with Deep Anterior Lamellar Keratoplasty.

Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH
2022

Histological findings of corneal tissue after failed phototherapeutic keratectomy in macular corneal dystrophy - a case report.

BMC ophthalmology
2022

Generation of iPSC line (GLNNFi001-A) from peripheral blood mononuclear cells of a patient with macular corneal dystrophy.

Stem cell research
2023

The alterations of corneal biomechanics in adult patients with corneal dystrophy.

Eye (London, England)
2022

Association of macular corneal dystrophy with excessive cell senescence and apoptosis induced by the novel mutant CHST6.

Experimental eye research
2021

Macular corneal dystrophy related to novel mutations of CHST6 in a Chinese family and clinical observation after penetrating keratoplasty.

BMC medical genomics
2021

Medium-Term Clinical Outcomes of Deep Anterior Lamellar Keratoplasty versus Penetrating Keratoplasty for Macular Corneal Dystrophy.

Clinical ophthalmology (Auckland, N.Z.)
2021

Detailed corneal and genetic characteristics of a pediatric patient with macular corneal dystrophy - case report.

BMC ophthalmology
2021

Novel compound heterozygous mutations in the CHST6 gene cause macular corneal dystrophy in a Han Chinese family.

Annals of translational medicine
2021

Macular Corneal Dystrophy: An Updated Review.

Current eye research
2020

Impairment of the autophagy-lysosomal pathway and activation of pyroptosis in macular corneal dystrophy.

Cell death discovery
2020

Recurrence of macular corneal dystrophy on the graft 50 years after penetrating keratoplasty.

GMS ophthalmology cases
2020

Bilateral phototherapeutic keratectomy for corneal macular dystrophy in an adolescent: case report and review of the literature.

Ophthalmic genetics
2020

Phototherapeutic Keratectomy in Macular and Granular Dystrophy: Two-year Results.

Seminars in ophthalmology
2020

CHST6 mutations identified in Iranian MCD patients and CHST6 mutations reported worldwide identify targets for gene editing approaches including the CRISPR/Cas system.

International ophthalmology
2020

Characterization of In Vivo Biomechanical Properties in Macular Corneal Dystrophy.

American journal of ophthalmology
2019

Macular corneal dystrophy with isolated peripheral Descemet membrane deposits.

American journal of ophthalmology case reports
2020

Distinct ocular surface soluble factor profile in human corneal dystrophies.

The ocular surface
2019

Establishment of a non-integrate iPS cell line CSUASOi002-A, from urine-derived cells of a female patient with macular corneal dystrophy carrying compound heterozygous CHST6 mutations.

Stem cell research
2019

Deep anterior lamellar keratoplasty outcomes in macular and granular corneal dystrophy - A comparative cross-sectional study.

Indian journal of ophthalmology
2019

Clinical diversity in macular corneal dystrophy: an optical coherence tomography study.

International ophthalmology
2019

A comprehensive evaluation of 181 reported CHST6 variants in patients with macular corneal dystrophy.

Aging
2019

Phenotype of macular corneal dystrophy in Labrador Retrievers: A multicenter study.

Veterinary ophthalmology
2019

Atypical presentation of macular corneal dystrophy managed by Descemet stripping endothelial keratoplasty.

Indian journal of ophthalmology
2019

[Corneal dystrophies in optical coherence tomography].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
2018

Outcome of deep anterior lamellar keratoplasty patients with intraoperative Descemet's membrane perforation: A retrospective cross-sectional study.

Indian journal of ophthalmology
2018

Primary graft failure after big bubble deep anterior lamellar keratoplasty in macular corneal dystrophy.

Indian journal of ophthalmology
2018

Simultaneous Presence of Macular Corneal Dystrophy and Retinitis Pigmentosa in Three Members of a Family.

Iranian journal of medical sciences
2018

Macular corneal dystrophy: A review.

Survey of ophthalmology
2017

CHST6 mutation screening and endoplasmatic reticulum stress in macular corneal dystrophy.

Oncotarget
2018

Triple chamber: a clinical rarity after deep anterior lamellar keratoplasty and role of optical coherence tomography in management.

International ophthalmology
2018

Infective keratitis in Indian patients with corneal dystrophies.

Tropical doctor
2016

Genetic analysis of CHST6 and TGFBI in Turkish patients with corneal dystrophies: Five novel variations in CHST6.

Molecular vision
2016

A Carbohydrate Sulfotransferase-6 (CHST6) gene mutation is associated with Macular Corneal Dystrophy in Labrador Retrievers.

Veterinary ophthalmology
2016

Macular Corneal Dystrophy and Posterior Corneal Abnormalities.

Cornea
2016

Establishment of an in vitro monolayer model of macular corneal dystrophy.

Laboratory investigation; a journal of technical methods and pathology
2016

Novel mutation in the CHST6 gene causes macular corneal dystrophy in a black South African family.

BMC medical genetics
2016

Excimer laser phototherapeutic keratectomy in conjunction with mitomycin C in corneal macular and granular dystrophies.

Arquivos brasileiros de oftalmologia
2016

Mutational spectrum of Korean patients with corneal dystrophy.

Clinical genetics
2015

Molecular analysis of the CHST6 gene in Korean patients with macular corneal dystrophy: Identification of three novel mutations.

Molecular vision
2016

Femtosecond Laser-Assisted Lamellar Keratectomy for Corneal Opacities Secondary to Anterior Corneal Dystrophies: An Interventional Case Series.

Cornea
2015

In vivo Confocal Microscopic Analysis of Limbal Stroma in Patients With Limbal Stem Cell Deficiency.

Cornea
2015

Deep Anterior Lamellar Keratoplasty in Macular Corneal Dystrophy.

Cornea
2015

Prevalence and histopathological characteristics of corneal stromal dystrophies in Saudi Arabia.

Middle East African journal of ophthalmology
2015

Collagen Fibrils and Proteoglycans of Macular Dystrophy Cornea: Ultrastructure and 3D Transmission Electron Tomography.

Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada
2015

Corneal topography analysis of stromal corneal dystrophies.

Pakistan journal of medical sciences
2015

A novel proteotoxic stress associated mechanism for macular corneal dystrophy.

Histology and histopathology
Ver todos os 159 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia corneana, tipo macular.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia corneana, tipo macular

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Targeted AAV6 gene therapy restores corneal endothelial function in three hereditary corneal dystrophies.
    Cell reports. Medicine· 2026· PMID 41850243mais citado
  2. Molecular characterization of CHST6 in Egyptian families with macular corneal dystrophy reveals recurrent and novel variants.
    Ophthalmic genetics· 2026· PMID 41566685mais citado
  3. Keratan sulfate revisited: UPLC-MS/MS-based quantitative profiling reveals structural heterogeneity and deficiency in ocular pathologies.
    Carbohydrate polymers· 2026· PMID 41475749mais citado
  4. Objective assessment of graft clarity and recurrence after penetrating keratoplasty for granular, lattice and macular corneal dystrophy using scheimpflug densitometry.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie· 2026· PMID 41396443mais citado
  5. Understanding the role of hydration and hydration gradient in corneal disease.
    Experimental eye research· 2026· PMID 41213352mais citado
  6. Evaluation of the corneal endothelium in clear grafts after deep anterior lamellar keratoplasty using specular microscopy.
    Int Ophthalmol· 2026· PMID 41961333recente
  7. Scanning electron microscopy of the descemet membrane in macular corneal dystrophy.
    Eur J Ophthalmol· 2026· PMID 41847721recente
  8. Anterior Segment Optical Coherence Tomography in the Diagnosis of Corneal Stromal Dystrophies in Romania.
    Maedica (Bucur)· 2025· PMID 41537071recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98969(Orphanet)
  2. OMIM OMIM:217800(OMIM)
  3. MONDO:0009020(MONDO)
  4. GARD:6953(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q4385926(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia corneana, tipo macular
Compêndio · Raras BR

Distrofia corneana, tipo macular

ORPHA:98969 · MONDO:0009020
Prevalência
1-9 / 100 000
Herança
Autosomal recessive
CID-10
H18.5 · Distrofias hereditárias da córnea
CID-11
Início
All ages
Prevalência
1.0 (United States)
MedGen
UMLS
C0024439
Testes
23 disponíveis
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades